Quetiapine (Seroquel) Off-Label Use in Personal Injury Claims

Understand risks and appropriateness of antipsychotics for sleep and anxiety

Published: 3 April 2026 | Updated: 3 April 2026

The Quetiapine Conundrum in Claims

Quetiapine is an atypical antipsychotic approved for schizophrenia, bipolar disorder, and major depression. However, in Australia and New Zealand, it's increasingly prescribed off-label for insomnia and anxiety in personal injury claims. While some off-label use is clinically appropriate, quetiapine for sleep or anxiety without documented psychosis or mood disorder raises questions about appropriateness, tolerability, and long-term risk. For insurers, quetiapine represents a particularly complex medication decision because the evidence supporting its off-label use is limited, yet the medication carries significant metabolic and neurological risks that extend far beyond approved indications. You need clear criteria to identify when quetiapine is justified and when it represents therapeutic drift or overprescribing.

Quetiapine Pharmacology and Off-Label Use

Quetiapine is a broadspectrum antagonist at dopamine D2, serotonin 5HT2a, and histamine H1 receptors. Its antipsychotic effect comes from dopamine antagonism at D2 receptors; its sedation comes from histamine H1 antagonism and anticholinergic properties. At low doses (25 to 200mg), histamine antagonism is pronounced, producing sedation. This has led many prescribers to use quetiapine as a hypnotic or anxiolytic, particularly when SSRIs have failed or benzodiazepines are avoided.

Common Off-Label Scenarios in Claims

• Insomnia: Claimant prescribed quetiapine 50 to 200mg nightly despite no psychotic or mood disorder diagnosis
• Anxiety or PTSD: Quetiapine added to or substituted for SSRI without documented response to SSRI or formal indication for antipsychotic
• Agitation or behavioral disturbance: Quetiapine prescribed for emotional dysregulation secondary to injury without evidence of psychotic symptoms
• Pain-related insomnia: Quetiapine used because "all other options failed," despite limited evidence for pain-related insomnia

Metabolic and Cardiometabolic Risks

This is where the risk-benefit analysis shifts unfavorably. Unlike zolpidem or zopiclone, which carry mainly neurological risks, quetiapine carries significant metabolic burden:

Weight Gain and Metabolic Syndrome

Quetiapine use is associated with weight gain, averaging 1 to 2kg over 8 to 12 weeks. In claimants recovering from injury and attempting return-to-work, weight gain impairs functional capacity, increases pain, and can delay mobility-based rehabilitation. Metabolic syndrome develops in some users, with dyslipidemia, hypertension, and impaired glucose tolerance emerging. In a claimant already managing injury-related physiological stress, quetiapine-induced metabolic changes are counterproductive.

Glucose Intolerance and Diabetes Risk

Atypical antipsychotics, including quetiapine, impair glucose metabolism. While diabetes development is rare with short-term use, claimants on quetiapine for months or years face elevated risk. Some develop frank hyperglycemia within weeks. This is particularly relevant in older claimants or those with obesity or family history of diabetes.

Prolactin Elevation

Quetiapine elevates prolactin levels, though less than some other antipsychotics. Effects include sexual dysfunction, gynecomastia, and galactorrhea. In claimants on quetiapine for insomnia or anxiety (conditions without biological basis for antipsychotic treatment), prolactin-related side effects are difficult to justify to the claimant.

Sudden Cardiac Death Risk

Some evidence suggests antipsychotics may prolong QTc interval, rarely leading to torsades de pointes. This risk is low with quetiapine alone but increases with concurrent QTc-prolonging medications or electrolyte abnormalities. In polypharmacy scenarios, this becomes a consideration.

Assessment Framework for Quetiapine Off-Label Use

Key Questions to Ask Your Prescriber

When you identify quetiapine use, ask the prescriber explicitly:

• "What is the documented indication for quetiapine in this claimant?" (Expect specific diagnosis; "insomnia" or "anxiety alone" is insufficient.)
• "Has an SSRI/SNRI been trialed at therapeutic dose for adequate duration before antipsychotic consideration?" (For mood-related indications.)
• "What is the plan for duration of treatment? When will deprescribing be considered?" (Off-label antipsychotics should not be indefinite without clear rationale.)
• "Has metabolic screening occurred? When was it last reviewed?" (Weight, fasting glucose, lipid profile, blood pressure.)
• "Are alternatives available that align better with evidence-based guidelines?" (Direct prescriber to consider non-pharmacological or approved pharmacological alternatives.)

Metabolic Monitoring for Quetiapine Users

If quetiapine continuation is justified, mandatory monitoring must occur:

When to Escalate

• Weight gain exceeding 5 percent from baseline
• Fasting glucose elevation or HbA1c rise to prediabetic range
• Blood pressure elevation requiring antihypertensive
• Severe sexual dysfunction or other intolerable side effects
• No documented clinical benefit after 8 to 12 weeks

Deprescribing Quetiapine Off-Label Use

If quetiapine is identified as off-label with insufficient clinical justification, deprescribing should proceed thoughtfully. Abrupt cessation may cause rebound insomnia, anxiety, or emotional dysregulation. A gradual dose reduction over 4 to 8 weeks is preferred, with concurrent introduction of alternative sleep support or psychological therapy.

Alternative Management Strategies

For Off-Label Insomnia

• Melatonin: 2 to 5mg at bedtime; no metabolic risk; supports circadian rhythm
• Amitriptyline: 10 to 25mg at bedtime; mood and pain benefit; no metabolic risk
• CBT-I: First-line for insomnia; sustained benefit; no medication burden

For Off-Label Anxiety or PTSD

• SSRI/SNRI optimization: Ensure adequate dose and duration before antipsychotic consideration
• CBT or trauma-focused therapy: Evidence-based psychological treatment
• Buspirone: Non-sedating anxiolytic without metabolic risk

Your Role in Quetiapine Governance

• Before approval: Request indication documentation. If off-label (insomnia or anxiety alone), seek clinical justification or direct deprescribing discussion.
• During use: Mandate metabolic monitoring at baseline, 12 weeks, and annually. Ensure weight and glucose are tracked.
• At 6 months: If off-label use identified, request deprescribing plan with alternative specified.
• Ongoing: If clinically justified continuation, reaffirm indication annually and ensure benefits exceed metabolic risks.